Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y₁₂ Inhibitor Therapy: The CAMEO Registry.

ABSTRACT:

Background

Little is known about the bleeding risk associated with cangrelor use in patients with myocardial infarction (MI) who are exposed to an oral P2Y₁₂ inhibitor before coronary angiography.

Methods

Cangrelor in Acute MI: Effectiveness and Outcomes (CAMEO) is an observational registry studying platelet inhibition for patients with MI. Upstream oral P2Y₁₂ inhibition was defined as receipt of an oral P2Y₁₂ inhibitor within 24 hours before hospitalization or in-hospital before angiography. Among cangrelor-treated patients, we compared bleeding after cangrelor use through 7 days postdischarge between patients with and without upstream oral P2Y₁₂ inhibitor exposure.

Results

Among 1802 cangrelor-treated patients with MI, 385

SUBMITTER: Rymer J 

PROVIDER: S-EPMC11308101 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature